• Pasithea Therapeutics will host a virtual NF1 treatment event on November 4, 2026, at 11 a.m. ET.
• Experts will discuss unmet needs in NF1-associated cutaneous and plexiform neurofibromas.
• Management will review PAS-004's Phase 1 solid tumor data and commercial opportunity in NF1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610281605PRIMZONEFULLFEED9855489) on October 28, 2026, and is solely responsible for the information contained therein.